Cerus Corporation received FDA approval in the U.S. for its INTERCEPT Blood System and is headquartered in Concord, CA.
2 reports, 1 independent
Updated Jul 23
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cerus Corporation received FDA approval in the U.S. for its INTERCEPT Blood System and is headquartered in Concord, CA.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.INTERCEPT Blood System received FDA approval in the U.S.1 source
- Product certification process underway for INTERCEPT RBC via SÚKL/TÜV-SÜD.
Keep exploring
The entities involved
-
Cerus Corporation
US-based reduced-pathogen blood biotechnology company
Nothing else this week.
- FDA
Related events
- Cerus Corporation and TransMedics Group, Inc. are competing against each other for investment funding.
- A network focused on cell and gene therapies is expanding to include sites in Northern California, involving the CA Institute for Regenerative Medicine and the FDA.
- FDA-approved products are subject to Controlled Substances Act rules, impacting TerrAscend's operations across Pennsylvania, Maryland, New Jersey, and Ohio.
- Beren Therapeutics' medicine is under FDA review, coinciding with a CNS meeting held in Montréal, Canada.
Coverage
Newest first; wire copies grouped- Business WireCerus Corporation to Release Second Quarter 2025 Financial Results on August 5, 2025 CONCORD, Calif., July 22, 2025--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) announced today that its second
- Unknown outlet